Savara, Inc.

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On April 14, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to 24 new employees who recently joined the Company. The inducement awards consist of options to purchase 18,500 shares of the Company’s common stock, restricted stock units (RSUs) covering 141,000 shares of the Company’s common stock, and performance stock units (PSUs) covering 85,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company. The options have an exercise price of $6.07 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16 th of the number of shares subject to the option on each quarterly anniversary of the employee’s first day of employment, subject to the employee’s continued employment on each such vesting date. The RSUs vest in full on the two-year anniversary of the employee’s first day of employment, and PSUs vest in full upon the date the Company reports quarterly revenue above a specified target, in each case subject to the employee’s continued employment on such vesting date. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow ® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at , and LinkedIn . *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc. Contacts Media and Investor Relations Contact Savara Inc. Temre Johnson, Executive Director, Corporate Affairs ir@savarapharma.com

💰 MeiraGTx buys back eye gene therapy from J&J for just $25M: The gene therapy, known as bota-vec, failed a Phase 3 study for X-linked retinitis pigmentosa (XLRP) last year. But physicians and patient advocates believed the data showed the gene therapy still had promise, and urged J&J to at least apply to regulators for approval. However, J&J did not do so. The big pharma had bought a suite of therapies including bota-vec from MeiraGTx for $100 million upfront in 2019. Now, MeiraGTx will be taking bota-vec back for $25 million. The London and New York-based biotech “intends to immediately pursue global regulatory filings for approval of bota-vec,” it said Thursday morning. MeiraGTx also announced a $100 million public offering that’s in part meant to fund the launch of bota-vec. — Lei Lei Wu 💵 STORM Therapeutics hauls in $56M Series C : The cancer-focused biotech will put the cash towards an asset called STC-15, a pill that blocks the RNA-modifying enzyme METTL3. The drug recently entered a Phase 2 study in selected sarcomas. Investors in the round included M Ventures, Pfizer Ventures and Taiho Ventures. — Elizabeth Cairns 💰 Adlai Nortye nabs $150M private placement: The biotech is developing a number of immuno-oncology programs and recently started human studies for a pan-RAS inhibitor. The RAS area is hot after Revolution Medicines’ Phase 3 pancreatic cancer trial succeeded earlier this week. — Max Gelman ⌚ FDA delays approval decision for Savara’s lung disease drug : The agency pushed the PDUFA date for molgramostim, Savara’s therapy for the rare condition autoimmune pulmonary alveolar proteinosis, back three months to Nov. 22. Savara recently submitted more information at the FDA’s request, and the FDA needs more time to assess it. — Elizabeth Cairns 🍎 Another twist in Apple Tree Partners’ bankruptcy case: A US bankruptcy judge will allow the VC firm’s bankruptcy case to proceed, rejecting arguments from its main funder Rigmora Holdings that the fund and its general partner were not in financial distress. But the judge also lifted a stay on certain aspects of parallel proceedings in the Cayman Islands, where Rigmora was seeking to wind up the partnership. A Cayman judge will now hear arguments that Rigmora lost confidence in Apple Tree to manage the fund, and about whether the fund “lost its substratum.” It isn’t immediately clear what impact the decision will eventually have on Apple Tree’s portfolio companies, many of which are in dire shape. But for now, both sides are claiming the decision as a victory. — Nicole DeFeudis 🤝 Aligos Therapeutics secures China license for hepatitis B treatment: Aligos will get $25 million upfront from Xiamen Amoytop Biotech, in exchange for a license to the chronic hepatitis B therapy pevifoscorvir sodium. Amoytop’s license includes China, Taiwan, Hong Kong and Macau. Aligos is eligible for another $420 million in milestone payments. Interim Phase 2 data are expected in the second half of this year, with topline results likely in 2027. — Max Gelman Longevity biotech Nula debuts with up to $30 million in funding: That includes a previously announced award of up to $20 million from ARPA-H. The biotech, which raised another $10 million from Apollo Health Ventures, is developing small molecule drugs targeted at the nuclear envelope and will first be focusing on metabolic dysfunction. The startup is led by Christopher Shepard, who is also a partner at Apollo. — Lei Lei Wu

The FDA has extended its review of Savara's Molbreevi (molgramostim) for autoimmune pulmonary alveolar proteinosis (aPAP) by three months to November 22, seeking additional time to assess newly submitted materials by the company.The PDUFA extension was triggered after the FDA determined that Savara's responses to recent information requests constituted a major amendment to Molbreevi's marketing application. The biotech, however, noted the agency did not raise any safety, efficacy or manufacturing concerns with the investigational therapy in its correspondence.The latest development marks yet another setback in a protracted regulatory journey for the inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). In early 2025, the FDA refused to file the original application, citing insufficient chemistry, manufacturing and controls (CMC) data — though no safety or efficacy concerns were highlighted at that time as well. Savara subsequently resubmitted its application late last year following remediation of the CMC deficiencies.Meanwhile, Molbreevi's clinical development trajectory has been equally turbulent. In 2019, the therapy fell short in the Phase III IMPALA trial in aPAP, failing to improve the alveolar-arterial oxygen gradient versus placebo. The therapy, however, redeemed itself four years later by meeting the primary endpoint in the pivotal IMPALA-2 study — though the readout drew a muted investor response.Molbreevi also remains under regulatory review in the EU for aPAP. Jefferies analysts earlier projected the drug — gained through Savara's acquisition of Serendex Pharmaceuticals — could surpass $400 million in peak US sales.